GENES AND GENES COMBINATIONS BASED ON GENE MKNK1 PREDICTIVE OF EARLY RESPONSE OR NON RESPONSE OF SUBJECTS SUFFERING FROM INFLAMMATORY DISEASE TO CYTOKINE TARGETING DRUGS (CYTD) OR ANTI-INFLAMMATORY BIOLOGICAL DRUGS
This invention refers to the field of human medicine and specifically to the diagnosis/prognosis of the responsiveness to a cytokine targeting drug (Cy TD) or an anti-inflammatory biological drug treatment of a subject suffering from an inflammatory disease. More precisely, the present invention concerns a method for the in vitrodiagnosis/prognosis of a Cy TD or an anti-inflammatory biological drug responsive or non-responsive phenotype, comprising: (a) determining from a subject biological sample an expression profile comprising the gene MKNK1； or of the genes MKNK1 and GNLY； or of the genes MKNK1, TBX21 and TGFBR3； or of the genes MKNK1, GNLY, and ADI1； or of the genes MKNK1, GNLY, ADI1, and IL1B； or of the genes MKNK1, GNLY, ADI1, IL1B, and IL1R1； or of the genes MKNK1, PRF1, TBX21, TGFBR3, IFNGR2, FYN, IL1B and CFLAR； or of the genes MKNK1, PRF1, TBX21, TGFBR3, IFNGR2, FYN, IL1B, CFLAR, MAPK14 and GNLY； or of the genes MKNK1, PRF1, TBX21, TGFBR3, IFNGR2, FYN, IL1B, CFLAR, CD14 and TGFBR2； or of the genes MKNK1, IFNGR2, IL1B, MAPK14, GNLY, and CD14； or of the genes MKNK1, PRF1, TBX21, TGFBR3, IFNGR2, IL1B, CFLAR, MAPK14, GNLY, CD14 and TGFBR2； or of all the 46 genes of following Tables 2, 3 and 4； or Equivalent Expression Profile thereof, provided that, in said Equivalent Expression Profile thereof, MKNK1 is not replaced by gene S 100A8 nor gene MAPK14, and (ii) optionally one or more housekeeping gene(s), (b) comparing the obtained expression profile with at least one reference expression profile, and (c) determining the responsive or non-responsive phenotype from said comparison. The present invention also relates to kits and nucleic acid microarrays for performing said method. The present invention also relates to methods of treatment of inflammatory disease-suffering patients.
